Table 1.
Patient characteristics with nivolumab in recurrent or metastatic head and neck cancer.
| Variables | N (= 126) | % |
|---|---|---|
| Age | ||
| < 69 | 67 | 53 |
| ≥ 69 | 59 | 47 |
| Sex | ||
| Male | 104 | 83 |
| Female | 22 | 17 |
| Primary tumor site | ||
| Oral cavity | 12 | 9 |
| Nasopharynx | 11 | 9 |
| Oropharynx | 27 | 21 |
| Hypopharynx | 20 | 16 |
| Larynx | 21 | 17 |
| Sinonasal cavity | 13 | 10 |
| Salivary gland | 8 | 6 |
| External ear canal | 7 | 6 |
| Unknown | 7 | 6 |
| ECOG PS | ||
| 01 | 102 | 81 |
| 2–3 | 24 | 19 |
| Site of recurrence | ||
| Loco-regional | 54 | 43 |
| Distant | 72 | 57 |
| Platinum sensitivity | ||
| Sensitive | 58 | 46 |
| Refractory | 68 | 54 |
| Modified Glasgow Prognostic Score | ||
| 0 | 70 | 56 |
| 1 | 12 | 10 |
| 2 | 35 | 27 |
| Unknown | 9 | 7 |
| Relative eosinophil count | ||
| < 1.5 | 71 | 56 |
| ≥ 1.5 | 53 | 42 |
| Unknown | 2 | 2 |
| Neutrophil/lymphocyte ratio | ||
| < 5 | 71 | 56 |
| ≥ 5 | 53 | 43 |
| Unknown | 1 | 1 |
| Platelet/lymphocyte ratio | ||
| < 253 | 62 | 49 |
| ≥ 253 | 63 | 50 |
| Unknown | 1 | 1 |
ECOG PS, Eastern Cooperative Oncology Group Performance Status.